⌕
Sarepta Therapeutics · SRPT · Nasdaq
Tenet 48 · Mixed
Compare
$14.77−2.38%At closeTenet 48 · Mixed
$14.77−0.36 (−2.38%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Sarepta Therapeutics (SRPT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● MarketBeatNov 9, 2026 · 17:12 ET
Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance

Sarepta Therapeutics NASDAQ: SRPT expects updates from its experimental neuromuscular disease programs to help shape its next phase of growth, while relying on its Duchenne muscular dystrophy business to fund development…

● Seeking AlphaNov 7, 2026 · 22:14 ETEARNINGS EXPECTED BY FEB 1
Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript

Sarepta Therapeutics, Inc. ( SRPT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO & Director Patrick M…

● Zacks Investment ResearchNov 6, 2026 · 11:26 ETEARNINGS EXPECTED BY FEB 1
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline

Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.…

● MarketBeatNov 6, 2026 · 04:16 ETEARNINGS EXPECTED BY FEB 1
Sarepta Therapeutics Q3 Earnings Call Highlights

Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-…

● Zacks Investment ResearchNov 5, 2026 · 20:31 ETEARNINGS EXPECTED BY FEB 1
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to W…

● Business WireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 1
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2026. “After my first 90 …

● Zacks Investment ResearchOct 29, 2026 · 11:02 ETEARNINGS EXPECTED BY FEB 1
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Business WireOct 26, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Sarepta Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming i…

● Business WireOct 22, 2026 · 08:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 1
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market clo…

● Defense WorldOct 19, 2026 · 08:14 ETEARNINGS EXPECTED BY FEB 1
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)

Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses…

● Business WireOct 14, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleot…

● BenzingaOct 6, 2026 · 08:17 ET
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock.…

● Business WireOct 5, 2026 · 13:26 ETCOMPANY'S OWN WORDS
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation in…

● Defense WorldOct 5, 2026 · 08:07 ET
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright

Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report)'s stock had its "sell" rating reissued by HC Wainwright in a research report issued on Monday, MarketBeat.com reports. They currently have a $5.00 target price on the…

● Business WireSep 30, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compen…

● Business WireSep 30, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (W…

● Business WireSep 25, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystro…

● Business WireSep 24, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientifi…

● Defense WorldSep 16, 2026 · 04:24 ETEARNINGS EXPECTED BY FEB 1
Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT

Squarepoint Ops LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Com…

● MarketBeatSep 15, 2026 · 01:03 ET
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or…

● Seeking AlphaSep 14, 2026 · 14:21 ET
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● BenzingaSep 8, 2026 · 13:47 ET
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1).…

● ReutersSep 8, 2026 · 13:02 ET
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-t…

● Business WireSep 8, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for th…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 1. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just SRPT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.